long intergenic non-protein coding RNA 967Genealiases: []
Q-omics provides the consensus-scored LINC00967 profile across patient tissues and cancer cell-line models. LINC00967 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC00967 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC00967 RNA expression shows 7,611 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight ACC, KIRC, and BLCA as cancer lineages where LINC00967 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00967 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00967 survival associations across molecular data types. LINC00967 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00967 RNA expression–survival associations across cancer types. High LINC00967 expression shows unfavorable associations in CHOL, THCA, ESCA and KICH, but favorable associations in ACC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC00967 RNA expression.
This table summarizes LINC00967 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00967. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00967 shows lower tumor expression in KIRC, STAD and KIRP and higher tumor expression in COAD, KICH and LIHC. The KIRC box plot shows higher LINC00967 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p < 0.001).
This table shows molecular features associated with LINC00967 in patient tissues and cancer cell lines. In patient samples, LINC00967 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
